One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
PainReform Ltd. logo
PainReform Ltd. PRFX
$ 0.76 3.8%
report update icon

Quarterly report 2025-Q4
added 05-07-2026

PainReform Ltd. Cash Flow 2025-2011 | PRFX

Brief overview of PainReform Ltd.'s cash flow quality

Cash flows are assessed across five available annual periods spanning 2021 to 2025.

Operating cash flow ended negative at -$4 million. Core operations are not yet producing a sustainable inflow.

Positive operating cash flow appeared only 0 times out of five; a stable cash profile has not formed.

What the cash flows show

PainReform Ltd. does not yet show sustainable internal cash generation. Stronger OCF and a return to free cash flow are needed.

Annual Cash Flow PainReform Ltd.

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-3.96 M -12.6 M -6.68 M -6.46 M -6.55 M -2.56 M -609 K -635 K - - - - - - -

Depreciation & Amortization

15 K 16 K 15 K 15 K 7 K - 1 K - - - - - - - -

Accounts Payables

213 K 296 K 221 K 209 K - 720 K - - - - - - - - -

All numbers in USD currency

Quarterly Cash Flow PainReform Ltd.

2025-Q4 2025-Q2 2024-Q4 2024-Q2 2023-Q4 2023-Q2 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

-3.96 M -1.98 M -12.6 M -8.64 M -6.68 M -3.96 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Depreciation & Amortization

15 K 9 K 16 K 8 K 15 K 6 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Accounts Payables

213 K 164 K 296 K 119 K 221 K 70 K - - - - 136 K - 57 K - 720 K - 13 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company PainReform Ltd., reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 13.17 0.77 % $ 1.18 B usaUSA
Seagen Seagen
SGEN
- - $ 42.2 B usaUSA
Codexis Codexis
CDXS
$ 1.29 4.88 % $ 112 M usaUSA
Cullinan Management Cullinan Management
CGEM
$ 14.89 0.4 % $ 897 M usaUSA
Compugen Ltd. Compugen Ltd.
CGEN
$ 2.12 -0.93 % $ 198 M israelIsrael
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 3.81 1.06 % $ 467 M usaUSA
Cellectar Biosciences Cellectar Biosciences
CLRB
$ 1.28 4.07 % $ 3.34 M usaUSA
Cocrystal Pharma Cocrystal Pharma
COCP
$ 0.96 1.81 % $ 10.8 M usaUSA
Collegium Pharmaceutical Collegium Pharmaceutical
COLL
$ 22.92 -1.36 % $ 725 M usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 4.29 -3.05 % $ 57.1 M usaUSA
Vascular Biogenics Ltd. Vascular Biogenics Ltd.
VBLT
- -8.77 % $ 12.4 M israelIsrael
Curis Curis
CRIS
$ 0.39 -1.9 % $ 5.13 M usaUSA
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
Corvus Pharmaceuticals Corvus Pharmaceuticals
CRVS
$ 10.05 -1.76 % $ 794 M usaUSA
Histogen Histogen
HSTO
- 31.6 % $ 2.12 M usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
$ 25.33 3.73 % $ 3.84 B usaUSA
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 6.51 1.31 % $ 284 M usaUSA
ImmunoGen ImmunoGen
IMGN
- - $ 7.92 B usaUSA
Denali Therapeutics Denali Therapeutics
DNLI
$ 18.68 -1.32 % $ 3.23 B usaUSA
Precision BioSciences Precision BioSciences
DTIL
$ 6.71 2.29 % $ 86.1 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 84.95 0.13 % $ 7.99 B usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
$ 37.18 1.47 % $ 2.16 B usaUSA
Editas Medicine Editas Medicine
EDIT
$ 2.51 -2.71 % $ 223 M usaUSA
Enanta Pharmaceuticals Enanta Pharmaceuticals
ENTA
$ 11.31 -3.08 % $ 241 K usaUSA
AIM ImmunoTech AIM ImmunoTech
AIM
$ 0.17 1.25 % $ 275 K usaUSA
Exelixis Exelixis
EXEL
$ 64.58 0.3 % $ 17.5 B usaUSA
Cidara Therapeutics Cidara Therapeutics
CDTX
- - $ 1.41 B usaUSA
Fortress Biotech Fortress Biotech
FBIO
$ 1.94 -0.26 % $ 54.1 M usaUSA
Iterum Therapeutics Iterum Therapeutics
ITRM
- - $ 591 K irlandaIrlanda
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 0.59 -5.31 % $ 152 M usaUSA
Galectin Therapeutics Galectin Therapeutics
GALT
$ 3.37 -1.75 % $ 215 M usaUSA
GeoVax Labs GeoVax Labs
GOVX
$ 0.23 2.25 % $ 220 K usaUSA
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
$ 8.76 -5.71 % $ 590 B britainBritain
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
GlaxoSmithKline plc GlaxoSmithKline plc
GSK
$ 50.02 -1.2 % $ 203 B britainBritain
GT Biopharma GT Biopharma
GTBP
$ 5.41 -25.99 % $ 29.8 M usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
$ 11.51 0.26 % $ 4.78 B irlandaIrlanda
Aldeyra Therapeutics Aldeyra Therapeutics
ALDX
$ 0.67 -8.72 % $ 40.2 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Kaleido Biosciences Kaleido Biosciences
KLDO
- -3.69 % $ 12.4 M usaUSA
Cyclerion Therapeutics Cyclerion Therapeutics
CYCN
$ 34.99 3.77 % $ 147 M usaUSA
Alector Alector
ALEC
$ 1.87 -5.08 % $ 193 M usaUSA
ObsEva SA ObsEva SA
OBSV
- -15.52 % $ 10.5 M schweizSchweiz
Kronos Bio Kronos Bio
KRON
- 1.49 % $ 50.8 M usaUSA
Landos Biopharma Landos Biopharma
LABP
- 0.58 % $ 144 M usaUSA
PhaseBio Pharmaceuticals PhaseBio Pharmaceuticals
PHAS
- 7.4 % $ 6.29 M usaUSA
Provention Bio Provention Bio
PRVB
- - $ 2.37 B usaUSA